Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and Eli Lilly and Co. (NYSE:LLY) also investing $15 million.